Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients
Alterations in the synthesis or enhanced inactivation of nitric oxide (NO) and an increase in endothelin-1 production lead to an imbalance that can induce arterial hypertension. Type II diabetes is characterized by impaired endothelium-dependent vasodilation and vascular disease. NO is produced thro...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2001
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 11974caa a22014657a 4500 | ||
|---|---|---|---|
| 001 | PAPER-2044 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518203122.0 | ||
| 008 | 190411s2001 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-0035871024 | |
| 024 | 7 | |2 cas |a Nitric Oxide, 10102-43-9; Tumor Necrosis Factor-alpha; von Willebrand Factor | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a THBRA | ||
| 100 | 1 | |a Ouvia, S.M. | |
| 245 | 1 | 0 | |a Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients |
| 260 | |c 2001 | ||
| 270 | 1 | 0 | |m Sassetti, B.; Departamento de Quimica Biologica, Fac. de Ciencias Exactas y Naturales, Universidad de Buenos Aires, 4 Piso, 1428 Buenos Aires, Argentina; email: sassetti@qb.fcen.uba.ar |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Cines, D.B., Polak, E.S., Buck, C.A., Loscalzo, J., Zimmerman, G.A., McEver, R.P., Pober, J.S., Stern, D.M., Endothelial cells in physiology and in the pathophysiology of vascular disorders (1998) Blood, 91, pp. 3527-3561 | ||
| 504 | |a DeMeyer, G.R.Y., Herman, A.G., Vascular endothelial dysfunction (1997) Prog Cardiovasc Dis, 39, pp. 325-342 | ||
| 504 | |a Moncada, S., Higgs, A., The L-arginine-nitric oxide pathway (1993) N Engl J Med, 27, pp. 2002-2011 | ||
| 504 | |a Stoiser, B., Maca, T., Thalammer, F., Hollenstein, U., El Menyawi, I., Burgmann, H., Serum nitrate concentration in patients with peripheral arterial occlusive disease (1999) Vasa, 28, pp. 181-184 | ||
| 504 | |a Ferlito, S., Gallina, M., Nitrite plasma levels in type 1 and 2 diabetes with and without complications (1998) Panminerva Med, 40, pp. 304-308 | ||
| 504 | |a Celermajer, D.S., Endothelial dysfunction: Does it matter? Is it reversible? (1997) JACC, 30, pp. 325-333 | ||
| 504 | |a Shimokawa, H., Endothelial dysfunction in hypertension (1998) J Atheroscler Thromb, 4, pp. 118-127 | ||
| 504 | |a Stehouwer, C.D.A., Schaper, N.C., The pathogenesis of vascular complications of diabetes mellitus: One voice or many? (1996) Eur J Clin Invest, 26, pp. 535-543 | ||
| 504 | |a Schmidt, A., Hori, O., Brett, J., Cellular receptors for AGEs: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis on vascular lesions (1994) Arterioscler Thromb, pp. 1521-1528 | ||
| 504 | |a Ferrannini, E., Haffner, S.M., Stern, M.P., Essential hypertension: An insulin resistence state (1990) Cardiovasc Pharmacol, 15, pp. 18-25 | ||
| 504 | |a Ferrannini, E., Buzzigoli, G., Bonadonna, R., Insulin resistance in essential hypertension (1987) N Engl J Med, 317, pp. 350-357 | ||
| 504 | |a DeFronzo, R.A., Ferrannini, E., Insulin resistance: A multifacetic syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease (1991) Diabetes Care, 14, pp. 173-194 | ||
| 504 | |a Tooke, J.E., Hannemann, M.M., Adverse endothelial function and the insulin resistance syndrome (2000) J Intern Med, 247, pp. 425-431 | ||
| 504 | |a Tachoepe, D., Rolsen, P., Schripper, B., Platelets in diabetes: The role in the hemostatic regulation in atherosclerosis (1993) Semin Thromb Haemostasis, 19, pp. 122-128 | ||
| 504 | |a Mc Ever, P.R., GMP-140: A receptor for neutrophils and monocytes on activated platelets and endothelium (1991) J Cell Biochem, 45, pp. 156-161 | ||
| 504 | |a Furie, B., Furie, B.C., The Molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: Role of P-selectin and the P-selectin ligand PSGL-1 (1995) Thromb Haemostasis, 74, pp. 224-227 | ||
| 504 | |a Fijnheer, R., Frijns, C.J., Korteweg, J., Rommes, H., Peters, J.H., Sixma, J.J., Nieuwenhuis, H.K., The origin of P-selectin as a circulating plasma protein (1997) Thromb Haemostasis, 77, pp. 1081-1085 | ||
| 504 | |a Blann, A.D., Lip, G.Y.H., Beevers, D.G., McCollum, C.N., Soluble P-selectin in atherosclerosis: A comparison with endothelial cell and platelet markers (1997) Thromb Haemostasis, 77, pp. 1077-1080 | ||
| 504 | |a Lip, G., Blann, A., Von Willebrand factor: A marker of endothelial dysfunction in vascular disorders? (1997) Cardiovasc Res, 34, pp. 255-265 | ||
| 504 | |a Mantovani, A., Bussolino, F., Dejana, E., Cytokine regulation of enthotelial cell function (1992) FASEB J, 6, pp. 2591-2599 | ||
| 504 | |a The sixth report of the Joint National Commmittee on Detection, Evaluation and Treatment of High Pressure (JNC VI) (1997) Arch Intern Med, 157, pp. 2413-2446 | ||
| 504 | |a Moshage, H., Kok, B., Huizenga, J.R., Jansen, P.L., Nitrite and nitrate determination in plasma: A critical evaluation (1995) Clin Chem, 41, pp. 892-896 | ||
| 504 | |a Michelson, A.D., Platelet activation by thrombine can be directely measured in whole blood through the use of peptide GPRP and flow cytometry: Methods and clinical applications (1994) Blood Coagulation Fibrinolysis, 5, pp. 121-131 | ||
| 504 | |a Brownlee, M., Advanced protein glycosylation in diabetes and aging (1995) Annu Rev Med, 46, pp. 223-234 | ||
| 504 | |a Bucala, R., Tracey, K.J., Cerami, A., Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes (1991) J Clin Invest, 87, pp. 432-438 | ||
| 504 | |a Kaplan, N.M., Primary hypertension: Pathogenesis (1998) Clinical hypertension. 7th ed., pp. 41-99. , Kaplan NM, editor. Baltimore, MD: Williams and Wilkins | ||
| 504 | |a Hausberg, M., Hoffman, R.P., Somers, V.K., Contrasting autonomic and hemodinamic effects of insulin in healthy elderly versus young subjects (1997) Hypertension, 29, pp. 700-705 | ||
| 504 | |a Cleland, S.J., Petrie, J.R., Small, M., Elliott, H.L., Connell, J.M., Insulin action is associated with endothelial function in hypertension and type 2 diabetes (2000) Hypertension, 35, pp. 507-511 | ||
| 504 | |a Radomski, M.W., Moncada, S., Regulation of vascular homeostasis by nitric oxide (1993) Thromb Haemostasis, 70, pp. 36-41 | ||
| 504 | |a Li, H., Fostermann, U., Nitric oxide in the pathogenesis of vascular disease (2000) J Pathol, 190, pp. 244-254 | ||
| 504 | |a Wu, C.-C., Yen, M.-H., Higher level of plasma nitric oxide in spontaneously hypertensive rats (1999) Am J Hypertens, 12, pp. 476-482 | ||
| 504 | |a Nava, E., Farré, A., Moreno, C., Casado, S., Moreau, P., Cosentino, F., Lüscher, T.F., Alterations to the nitric oxide pathway in the spontaneously hypertensive rat (1998) J Hypertens, 16, pp. 609-615 | ||
| 504 | |a Anggard, E., Nitric oxide: Mediator, murderer and medicine (1994) Lancet, 343, pp. 1199-1206 | ||
| 504 | |a Kodja, G., Harrison, D., Interaction between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure (1999) Cardiovasc Res, 43, pp. 562-571 | ||
| 504 | |a Vallejo, S., Angulo, J., Periro, C., Nevado, J., Sanchez-Ferrer, A., Petidier, R., Sanchez-Ferrer, C.F., Rodriguez-Manas, L., Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels (2000) Diabetologia, 43, pp. 83-90 | ||
| 520 | 3 | |a Alterations in the synthesis or enhanced inactivation of nitric oxide (NO) and an increase in endothelin-1 production lead to an imbalance that can induce arterial hypertension. Type II diabetes is characterized by impaired endothelium-dependent vasodilation and vascular disease. NO is produced through L-arginine pathway by three different isoforms of nitric oxide synthase (NOS), an inducible form that can be activated by cytokines such as tumor necrosis factor α (TNFα). We evaluated NO plasmatic levels, endothelial damage markers such as von Willebrand factor (vWF), platelet activation, soluble P-selectin (sP-Sel), TNFα levels, insulinaemia (I), glycosylated haemoglobin (HbA1c), glycaemia and blood pressure in 32 hypertensive diabetic type II patients (Group A), 37 hypertensive patients (Group B) and 35 healthy subjects (Group C) matched in sex, age, body mass index and dietary habits. The level of I was increased in patients compared to the controls and correlated with their NO levels. vWF plasmatic levels were increased in Group A compared to Groups B and C. We also found significant differences in platelet activation among all the groups. In diabetic patients, increased NO levels correlated with TNFα, HbA1c and platelet activation showed greater endothelial damage than in Group B. These parameters described a prothrombotic state associated with an insulin resistance state, an increased vWF release, raised sP-Sel and TNFα levels and, maybe, low NO bioavailability, which could lead to a higher risk of development of thrombotic events in hypertensive diabetic patients (Group A) than in the hypertensive patients in Group B. © 2001 Elsevier Science Ltd. |l eng | |
| 536 | |a Detalles de la financiación: Universidad de Buenos Aires, UBACYT TX22 | ||
| 536 | |a Detalles de la financiación: This work was supported by the Universidad de Buenos Aires, grant UBACYT TX22. | ||
| 593 | |a Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina | ||
| 593 | |a Hospital Churruca Visca, Buenos Aires, Argentina | ||
| 593 | |a Departamento de Qumica, Biolgica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pab. II, Piso, 1428 Buenos Aires, Argentina | ||
| 650 | 1 | 7 | |2 spines |a DIABETES |
| 690 | 1 | 0 | |a ENDOTHELIAL DYSFUNCTION |
| 690 | 1 | 0 | |a HYPERTENSION |
| 690 | 1 | 0 | |a NITRIC OXIDE |
| 690 | 1 | 0 | |a PLATELET ACTIVATION |
| 690 | 1 | 0 | |a VON WILLEBRAND FACTOR |
| 690 | 1 | 0 | |a ARGININE |
| 690 | 1 | 0 | |a ENDOTHELIN 1 |
| 690 | 1 | 0 | |a GLYCOSYLATED HEMOGLOBIN |
| 690 | 1 | 0 | |a NITRIC OXIDE |
| 690 | 1 | 0 | |a NITRIC OXIDE SYNTHASE |
| 690 | 1 | 0 | |a PADGEM PROTEIN |
| 690 | 1 | 0 | |a TUMOR NECROSIS FACTOR ALPHA |
| 690 | 1 | 0 | |a VON WILLEBRAND FACTOR |
| 690 | 1 | 0 | |a ADULT |
| 690 | 1 | 0 | |a AGED |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a BIOAVAILABILITY |
| 690 | 1 | 0 | |a BLOOD PRESSURE |
| 690 | 1 | 0 | |a BODY MASS |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a DIET |
| 690 | 1 | 0 | |a DISEASE MARKER |
| 690 | 1 | 0 | |a ENDOTHELIUM LESION |
| 690 | 1 | 0 | |a ENZYME ACTIVATION |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a GLUCOSE BLOOD LEVEL |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a HYPERTENSION |
| 690 | 1 | 0 | |a INSULIN BLOOD LEVEL |
| 690 | 1 | 0 | |a INSULIN RESISTANCE |
| 690 | 1 | 0 | |a INSULINEMIA |
| 690 | 1 | 0 | |a MAJOR CLINICAL STUDY |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a NON INSULIN DEPENDENT DIABETES MELLITUS |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a PROTEIN BLOOD LEVEL |
| 690 | 1 | 0 | |a THROMBOCYTE ACTIVATION |
| 690 | 1 | 0 | |a VASODILATATION |
| 690 | 1 | 0 | |a AGED |
| 690 | 1 | 0 | |a BLOOD PRESSURE |
| 690 | 1 | 0 | |a CASE-CONTROL STUDIES |
| 690 | 1 | 0 | |a DIABETES MELLITUS, TYPE 2 |
| 690 | 1 | 0 | |a ENDOTHELIUM, VASCULAR |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a HUMANS |
| 690 | 1 | 0 | |a HYPERTENSION |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a MIDDLE AGED |
| 690 | 1 | 0 | |a NITRIC OXIDE |
| 690 | 1 | 0 | |a PLATELET ACTIVATION |
| 690 | 1 | 0 | |a THROMBOPHILIA |
| 690 | 1 | 0 | |a TUMOR NECROSIS FACTOR-ALPHA |
| 690 | 1 | 0 | |a VON WILLEBRAND FACTOR |
| 700 | 1 | |a La Greca, R.D. | |
| 700 | 1 | |a Zanaro, N.L. | |
| 700 | 1 | |a Palmer, L. | |
| 700 | 1 | |a Sassetti, B. | |
| 773 | 0 | |d 2001 |g v. 102 |h pp. 107-114 |k n. 2 |p Thromb. Res. |x 00493848 |t Thrombosis Research | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035871024&doi=10.1016%2fS0049-3848%2801%2900237-7&partnerID=40&md5=b7316b09b6e309508ca6973492eabfe9 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S0049-3848(01)00237-7 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_00493848_v102_n2_p107_Ouvia |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00493848_v102_n2_p107_Ouvia |y Registro en la Biblioteca Digital |
| 961 | |a paper_00493848_v102_n2_p107_Ouvia |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 62997 | ||